Key result
Prasugrel treatment resulted in a 100% response rate based on VASP-PRI compared to 62-73% in the clopidogrel group, with only 7% of patients in the therapeutic range experiencing MACE.
Why the study?
Does VASP flow cytometry assay effectively monitor dual antiplatelet therapy efficacy in patients with acute STEMI post-PCI?
Population
Patients with acute STEMI post-PCI receiving dual antiplatelet therapy (clopidogrel or prasugrel and aspirin).
Design
Cohort
Follow-up
30 days
Authors
Loading...
Supports VASP-PRI for tailoring DAPT in STEMI; hypothesis-generating pending randomized confirmation.
Observational
Does VASP flow cytometry assay effectively monitor dual antiplatelet therapy efficacy in patients with acute STEMI post-PCI?
The VASP-phosphorylation assay may be a relevant method for guiding and tailoring dual antiplatelet therapy in post-PCI STEMI patients by effectively identifying therapeutic platelet reactivity.
Fedor et al. (2014) conducted an observational in Acute STEMI Post-PCI. Prasugrel vs. Clopidogrel was evaluated on Response rate based on VASP-platelet reactivity index (PRI). Prasugrel treatment resulted in a 100% response rate based on VASP-PRI compared to 62-73% in the clopidogrel group, with only 7% of patients in the therapeutic range experiencing MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: